Sharks ahoy Second on the list of J&J sales performers is Zytiga, at $556 million in Q1. Zytiga is approved for treating prostate cancer by stopping hormone production, but there are numerous other competitors coming into this field. The frontrunner is Medivation and Astellas' Xtandi, which had $357 million in sales in Q1, twice the sales of Q1 in 2014. This is compared to Zytiga operational sales growth of 19.2% year over year. Xtandi is projected to have U.S. sales in 2015 between $1.05 billion and $1.125 billion, which will certainly eat into J&J's market share. Currently, some insurance companies only cover Xtandi after the patient has tried Zytiga, but as Xtandi becomes more accepted as a primary treatment mechanism, particularly now that it has a chemotherapy-naive indication, this will be critical to keep an eye on. Provenge, an immunotherapy drug for the same type of cancer, is also competition in this field, and has recently been acquired by Valeant.